Trial Profile
Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis : Controlled Clinical Trial With Efficacy Assessment
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Jul 2021
Price :
$35
*
At a glance
- Drugs ECCS 50 (Primary)
- Indications Systemic scleroderma
- Focus Registrational; Therapeutic Use
- Acronyms SCLERADEC II
- 23 Jul 2021 Primary endpoint (Cochin hand functional scale) has not been met. according to the results published in the Rheumatology.
- 23 Jul 2021 Preliminary results assess the efficacy and safety of AD-SVF therapy in systemic sclerosis, published in the Rheumatology.
- 04 Mar 2019 Status changed from active, no longer recruiting to discontinued.